Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0479825/Endometrial-Cancer-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Endometrial Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Endometrial Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Endometrial Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts

Scope

The report provides information on the key drivers and challenges of the Endometrial Cancer Therapeutics market. Its Scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Endometrial Cancer Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Endometrial Cancer Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Endometrial Cancer Therapeutics therapeutics market.

- Analysis of key recent licensing and partnership agreements in Endometrial Cancer Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Endometrial Cancer Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Endometrial Cancer Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Endometrial Cancer Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Endometrial Cancer Therapeutics: Introduction 6

2.1 Overview 6

2.2 Epidemiology 6

2.3 Etiology 6

2.4 Symptoms 6

2.5 Diagnosis 7

2.6 Prognosis 7

2.7 Pathology 7

2.8 Staging 8

2.9 Treatment 10

2.10 GlobalData Pipeline Report Guidance 12

3 Endometrial Cancer Therapeutics: Market Characterization 13

3.1 Endometrial Cancer Therapeutics Market Size (2005-2010) – Global 13

3.2 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Global 14

3.3 Endometrial Cancer Therapeutics Market Size (2005-2010) – The US 15

3.4 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – The US 16

3.5 Endometrial Cancer Therapeutics Market Size (2005-2010) – France 17

3.6 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – France 18

3.7 Endometrial Cancer Therapeutics Market Size (2005-2010) – Germany 19

3.8 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Germany 20

3.9 Endometrial Cancer Therapeutics Market Size (2005-2010) – Italy 21

3.10 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Italy 22

3.11 Endometrial Cancer Therapeutics Market Size (2005-2010) – Spain 23

3.12 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Spain 24

3.13 Endometrial Cancer Therapeutics Market Size (2005-2010) – The UK 25

3.14 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – The UK 26

3.15 Endometrial Cancer Therapeutics Market Size (2005-2010) – Japan 27

3.16 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Japan 28

3.17 Drivers and Barriers 29

3.17.1 Drivers for the Endometrial Cancer Therapeutics Market 29

3.17.2 Barriers for the Endometrial Cancer Therapeutics Market 29

3.18 Opportunity and Unmet Need Analysis 30

3.19 Key Takeaway 30

4 Endometrial Cancer Therapeutics: Competitive Assessment 31

4.1 Overview 31

4.1.1 Strategic Competitor Assessment 31

4.2 Product Profiles for the Major Marketed Products in the Endometrial Cancer Therapeutics Market 32

4.2.1 Carboplatin plus Paclitaxel 32

4.2.2 Cisplatin Plus Doxorubicin 32

4.2.3 Cisplatin + Doxorubicin + Paclitaxel 33

4.2.4 Liposomal doxorubicin 34

4.2.5 Hormone therapies 34

4.3 Key Takeaway 34

5 Endometrial Cancer Therapeutics: Pipeline Assessment 35

5.1 Overview 35

5.2 Strategic Pipeline Assessment 35

5.3 Endometrial Cancer Therapeutics Pipeline – Pipeline by Clinical Phases of Development 35

5.4 Pipeline Analysis by Phase of Development 36

5.4.1 Endometrial Cancer Therapeutics – Phase III Pipeline 36

5.4.2 Endometrial Cancer Therapeutics – Phase II Pipeline 36

5.4.3 Endometrial Cancer Therapeutics – Phase I Pipeline 37

5.4.4 Endometrial Cancer Therapeutics – Preclinical Pipeline 37

5.5 Technology Trends Analytical Framework 38

5.6 Pipeline by Mechanism of Action 39

5.7 Endometrial Cancer Therapeutics – Promising Drugs Under Clinical Development 40

5.8 Molecule Profile for Promising Drugs Under Clinical Development 40

5.8.1 Ixempra 40

5.9 Key Takeaway 40

6 Endometrial Cancer Therapeutics: Clinical Trials Mapping 41

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 41

6.2 Clinical Trials by Phase 42

6.3 Clinical Trials by Trial Status 43

6.4 Overall Sponsors 44

6.5 Prominent Sponsors 45

6.6 Top Companies Participating in Therapeutics Clinical Trials 46

7 Endometrial Cancer Therapeutics: Strategic Assessment 48

7.1 Key Events Impacting the Future Market 48

7.2 Endometrial Cancer Therapeutics – Implications for Future Market Competition 49

8 Endometrial Cancer Therapeutics: Future Players 50

8.1 Introduction 50

8.2 Company Profiles 51

8.2.1 Bristol-Myers Squibb Company 51

8.2.2 AEterna Zentaris Inc 59

8.2.3 Ariad Pharmaceuticals Inc 62

8.2.4 Eisai Co., Ltd 64

8.2.5 EntreMed, Inc. 69

8.2.6 Exelixis, Inc. 71

8.2.7 Ipsen S.A. (Ipsen) 74

8.2.8 Merck & Co 77

8.2.9 Novartis AG 84

8.2.10 PharmaMar, S.A (Subsidiary of Zeltia, S.A.) 90

8.2.11 Sanofi-Aventis 91

8.3 Details of Other Companies in the Pipeline 95

9 Endometrial Cancer Therapeutics: Deals 96

10 Endometrial Cancer Therapeutics: Appendix 97

10.1 Market Definitions 97

10.2 Abbrevations 97

10.3 Research Methodology 98

10.3.1 Coverage 98

10.3.2 Secondary Research 98

10.3.3 Forecasting 98

10.3.4 Primary Research 101

10.3.5 Expert Panel Validation 102

10.4 Contact Us 102

10.5 Disclaimer 102

10.6 Bibliography 103

1.1 List of Tables

Table 1: Endometrial Cancer Therapeutics Market, Staging – TNM Classification 8

Table 2: Endometrial Cancer Therapeutics Market, – Staging Terminology 9

Table 3: Endometrial Cancer Therapeutics Market, Global, Revenue ($m), 2005–2010 13

Table 4: Endometrial Cancer Therapeutics Market, Global, Forecast ($m), 2010–2017 14

Table 5: Endometrial Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010 15

Table 6: Endometrial Cancer Therapeutics Market, the US, Forecast ($m), 2010–2017 16

Table 7: Endometrial Cancer Therapeutics Market, France, Revenue ($m), 2005–2010 17

Table 8: Endometrial Cancer Therapeutics Market, France, Forecast ($m), 2010–2017 18

Table 9: Endometrial Cancer Therapeutics Market, Germany, Revenue ($m), 2005–2010 19

Table 10: Endometrial Cancer Therapeutics Market, Germany, Forecast ($m), 2010–2017 20

Table 11: Endometrial Cancer Therapeutics Market, Italy, Revenue ($m), 2005–2010 21

Table 12: Endometrial Cancer Therapeutics Market, Italy, Forecast ($m), 2010–2017 22

Table 13: Endometrial Cancer Therapeutics Market, Spain, Revenue ($m), 2005–2010 23

Table 14: Endometrial Cancer Therapeutics Market, Spain, Forecast ($m), 2010–2017 24

Table 15: Endometrial Cancer Therapeutics Market, the UK, Revenue ($m), 2005–2010 25

Table 16: Endometrial Cancer Therapeutics Market, the UK, Forecast ($m), 2010–2017 26

Table 17: Endometrial Cancer Therapeutics Market, Japan, Revenue ($m), 2005–2010 27

Table 18: Endometrial Cancer Therapeutics Market, Japan, Forecast ($m), 2010–2017 28

Table 19: Endometrial Cancer Therapeutics Market, Therapeutics – Phase III Pipeline, Feb 2011 36

Table 20: Endometrial Cancer Therapeutics Market, Therapeutics – Phase II Pipeline, Feb 2011 36

Table 21: Endometrial Cancer Therapeutics Market, Therapeutics – Phase I Pipeline, Feb 2011 37

Table 22: Endometrial Cancer Therapeutics Market, Therapeutics – Preclinical Pipeline, Feb 2011 37

Table 23: Endometrial Cancer Therapeutics Market, Therapeutics – Most Promising Drugs Under Clinical Development, 2011 40

Table 24: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Country, 2010 41

Table 25: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Phase, 2010 42

Table 26: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Status, 2010 43

Table 27: Endometrial Cancer Therapeutics Market, Therapeutics – Prominent Sponsors, 2010 45

Table 28: Endometrial Cancer Therapeutics Market, Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2010 47

Table 29: Bristol-Myers Squibb Company, Pipeline, 2011 52

Table 30: Bristol-Myers Squibb Company Deals, 2009-2010 55

Table 31: AEterna Zentaris Inc, Oncology Pipeline, 2010 60

Table 32: AEterna Zentaris, Deals, 2009-2010 60

Table 33: Ariad Pharmaceuticals Inc, Oncology Pipeline, 2011 63

Table 34: Ariad Pharmaceuticals Inc, Deals, 2009-2010 63

Table 35: Eisai Co. Ltd, Oncology Pipeline, 2011 65

Table 36: Eisai Co. Ltd, Deals, 2009-2011 66

Table 37: EntreMed Inc, Oncology Pipeline, 2011 70

Table 38: EntreMed Inc, Deals, 2010 70

Table 39: Exelixis Inc., Pipeline, 2011 72

Table 40: Exelixis Inc., Deals, 2009-2010 73

Table 41: Ipsen S.A, Pipeline, 2011 75

Table 42: Ipsen S.A, Deals, 2009-2010 75

Table 43: Merck & Co., Inc, Oncology Pipeline, 2011 78

Table 44: Merck & Co., Inc, Deals, 2009-2010 78

Table 45: Novartis – Oncology Pipeline, 2010 86

Table 46: Novartis AG, Deals 87

Table 47: PharmaMar, S.A, Deals, 2009 90

Table 48: Sanofi-Aventis Oncology Pipeline, 2011 92

Table 49: Sanofi-Aventis Key Deals, 2010-2011 93

Table 50: Details of Other Companies in the Pipeline 95

Table 51: Endometrial Cancer Therapeutics Market, Therapeutics, Global, Deals, 2010 96

1.2 List of Figures

Figure 1: Endometrial Cancer Therapeutics Market, – Surgical Procedures 10

Figure 2: Endometrial Cancer Therapeutics Market, Global, Revenue ($m), 2005–2010 13

Figure 3: Endometrial Cancer Therapeutics Market, Global, Forecast ($m), 2010–2017 14

Figure 4: Endometrial Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010 15

Figure 5: Endometrial Cancer Therapeutics Market, the US, Forecast ($m), 2010–2017 16

Figure 6: Endometrial Cancer Therapeutics Market, France, Revenue ($m), 2005–2010 17

Figure 7: Endometrial Cancer Therapeutics Market, France, Forecast ($m), 2010–2017 18

Figure 8: Endometrial Cancer Therapeutics Market, Germany, Revenue ($m), 2005–2010 19

Figure 9: Endometrial Cancer Therapeutics Market, Germany, Forecast ($m), 2010–2017 20

Figure 10: Endometrial Cancer Therapeutics Market, Italy, Revenue ($m), 2005–2010 21

Figure 11: Endometrial Cancer Therapeutics Market, Italy, Forecast ($m), 2010–2017 22

Figure 12: Endometrial Cancer Therapeutics Market, Spain, Revenue ($m), 2005–2010 23

Figure 13: Endometrial Cancer Therapeutics Market, Spain, Forecast ($m), 2010–2017 24

Figure 14: Endometrial Cancer Therapeutics Market, the UK, Revenue ($m), 2005–2010 25

Figure 15: Endometrial Cancer Therapeutics Market, the UK, Forecast ($m), 2010–2017 26

Figure 16: Endometrial Cancer Therapeutics Market, Japan, Revenue ($m), 2005–2010 27

Figure 17: Endometrial Cancer Therapeutics Market, Japan, Forecast ($m), 2010–2017 28

Figure 18: Opportunity and Unmet Need in the Endometrial Cancer Therapeutics Market 30

Figure 19: Endometrial Cancer Therapeutics Market, Therapeutics – Strategic Competitor Assessment, 2010 31

Figure 20: Endometrial Cancer Therapeutics Market, Therapeutics – Pipeline by Phase of Clinical Development, Feb 2011 35

Figure 21: Endometrial Cancer Therapeutics Market, Therapeutics – Technology Trends Analytics Framework, Feb 2011 38

Figure 22: Endometrial Cancer Therapeutics Market, Therapeutics – Technology Trends Analytics Framework – Description, Feb 2011 38

Figure 23: Endometrial Cancer Therapeutics Market, Therapeutics – Pipeline by Mechanism of Action, 2011 39

Figure 24: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Country, 2010 41

Figure 25: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Phase, 2010 42

Figure 26: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Status, 2010 43

Figure 27: Endometrial Cancer Therapeutics Market, Therapeutics – Overall Sponsors, 2010 44

Figure 28: Endometrial Cancer Therapeutics Market, Therapeutics – Prominent Sponsors, 2010 45

Figure 29: Endometrial Cancer Therapeutics Market, Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2010 46

Figure 30: Endometrial Cancer Therapeutics Market, Therapeutics, Drivers and Restraints, 2010 48

Figure 31: Endometrial Cancer Therapeutics Market, Therapeutics – Implications for Future Market Competition, 2010 49

Figure 32: Endometrial Cancer Therapeutics Market, Therapeutics – Pipeline by Company, 2010 50

Figure 33: GlobalData Market Forecasting Model 101Bristol-Myers Squibb Company

AEterna Zentaris Inc

Ariad Pharmaceuticals Inc

Eisai Co., Ltd

EntreMed, Inc.

Exelixis, Inc.

Ipsen S.A. (Ipsen)

Merck & Co

Novartis AG

PharmaMar, S.A (Subsidiary of Zeltia, S.A.)

Sanofi-Aventis

To order this report:

: Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker